Are There Differences Between Women and Men After a Percutaneous Intervention?

Prior research has shown that women with coronary artery disease who undergo percutaneous revascularization present more comorbidities, require less aggressive treatments, have greater long-term morbidity rates and worst functional status and/or post-procedure angina.

This study used data from the CPORT-E trial (Cardiovascular Patient Outcomes Research Team Non primary Percutaneous Coronary Intervention) to assess baseline differences between sexes at 6 weeks and 9 months after the procedure.

The primary endpoint (PEP) was overall mortality at 6 weeks, while the secondary endpoint (SEP) was a composite of all-cause mortality, type Q acute myocardial infarction, and culprit vessel revascularization at 9 months.

Out of the 18,867 assessed patients, 6851 were women (36%). The women were older, more frequently of African-American origin, and had higher rates of hypertension, diabetes, heart failure, previous stroke, or peripheral vascular disease. In contrast, they had lower rates of prior angioplasty or myocardial revascularization surgery, prior myocardial infarction, and smoking.

In coronary angiography, women had more findings of single-vessel disease, and less frequently received multivessel angioplasty.

Read also: IVUS in Femoropopliteal PCI: Should We Start Using It?

While there were no differences between the PEP and the SEP, women had higher rates of bleeding, vascular repair, and repeat diagnostic catheterization. 

Significant differences were also observed in health status (measured by a Self-Assessment Questionnaire); they presented worse health status at 6 weeks and at 9 months at the expense of higher frequency of angina, worse quality of life, and physical limitations.

Conclusion

Being female was a predictor of worse health status at 6 weeks and at 9 months after angioplasty.

Dr. Andrés Rodríguez.
Member of the Editorial Board, SOLACI.org

Original Title: Sex Differences in Health Status and Clinical Outcomes After Nonprimary Percutaneous Coronary Intervention.

Reference: Pranoti G. Hiremath et al. Circ Cardiovasc Interv. 2022;15:e011308.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...